Despite numerous genome-wide association studies conducted in psoriasis and psoriatic arthritis, only a small fraction of the identified genes has been therapeutically targeted.
Objective:
We sought to identify and analyze potential therapeutic targets for psoriasis and psoriatic arthritis (PsA) using the priority index (Pi), a genetics-dependent drug target prioritization approach.
Methods:
Significant genetic variants from GWAS for psoriasis, PsA, and combined psoriatic disease were annotated and run through the Pi pipeline. Potential drug targets were identified based on genomic predictors, annotation predictors, pathway enrichment, and pathway crosstalk.
Results:
Several gene targets were identified for psoriasis and PsA that demonstrated biological associations to their respective diseases. Some are currently being explored as potential therapeutic targets (i.e. ICAM1, NF-kB, REV3 L, ADRA1B for psoriasis; CCL11 for PsA); others have not yet been investigated (i.e. LNPEP, LCE3 for psoriasis; UBLCP1 for PsA). Additionally, many nodal points of potential intervention were identified as promising therapeutic targets. Of these, some are currently being studied such as TYK2 for psoriasis, and others have yet to be explored (i.e. PPP2CA, YAP1, PI3 K, AKT, FOXO1, RELA, CSF2, IFNGR1, IFNGR2 for psoriasis; GNAQ, PLCB1, GNAI2 for PsA).
Conclusion:
Through Pi, we identified data-driven candidate therapeutic gene targets and pathways for psoriasis and PsA. Given the sparse PsA specific genetic studies and PsA specific drug targets, this analysis could prove to be particularly valuable in the pipeline for novel psoriatic therapies.
ParisiRSymmonsDPMGriffithsCEMAshcroftDM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.339
2.
RachakondaTDSchuppCWArmstrongAW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi:10.1016/j.jaad.2013.11.013
3.
NiCChiuMW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119–132. doi:10.2147/CCID.S44843
ChandranVRaychaudhuriSP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–J321. doi:10.1016/j.jaut.2009.12.001
6.
CaponF. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526. doi:10.3390/ijms18122526
7.
GladmanDDAntoniCMeasePCleggDONashO. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(suppl 2):ii14–ii17. doi:10.1136/ard.2004.032482
8.
MeasePJGladmanDDPappKA, et al.Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–735. doi:10.1016/j.jaad.2013.07.023
9.
RanzaRCarneiroSQureshiAA, et al.Prevalence of psoriatic arthritis in a large cohort of Brazilian patients with psoriasis. J Rheumatol. 2015;42(5):829–834. doi:10.3899/jrheum.140474
10.
RitchlinCTColbertRAGladmanDD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970. doi:10.1056/NEJMra1505557
11.
KofoedKSkovLZachariaeC. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015;95(2):133–139. doi:10.2340/00015555-1931
12.
ChimentiMSD’antonioAConigliaroP, et al.An update for the clinician on biologics for the treatment of psoriatic arthritis. Biologics. 2020;14:53–75. doi:10.2147/BTT.S260754
13.
NelsonMRTipneyHPainterJL, et al.The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856–860. doi:10.1038/ng.3314
14.
KingEAWade DavisJDegnerJF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15(12):e1008489. doi:10.1371/journal.pgen.1008489
15.
FangH,ULTRA-DD Consortium, De WolfHKnezevicB, et al.A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat Genet. 2019;51(7):1082–1091. doi:10.1038/s41588-019-0456-1
16.
CaoCMoultJ. GWAS and drug targets. BMC Genomics. 2014;15(suppl 4):S5. doi:10.1186/1471-2164-15-S4-S5
17.
MacNamaraANakicNAmin Al OlamaA, et al.Network and pathway expansion of genetic disease associations identifies successful drug targets. Sci Rep. 2020;10(1):20970. doi:10.1038/s41598-020-77847-9
PollockRAAbjiFLiangK, et al.Gene expression differences between psoriasis patients with and without inflammatory arthritis. J Invest Dermatol. 2015;135(2):620–623. doi:10.1038/jid.2014.414
21.
WangZMonteiroCDJagodnikKM, et al.Extraction and analysis of signatures from the gene expression omnibus by the crowd. Nat Commun. 2016;7:12846. doi:10.1038/ncomms12846
22.
BergboerJGMTjabringaGSKamsteegM, et al.Psoriasis risk genes of the late cornified envelope-3 group are distinctly expressed compared with genes of other LCE groups. Am J Pathol. 2011;178(4):1470–1477. doi:10.1016/j.ajpath.2010.12.017
23.
JacksonBTilliCMLJHardmanMJ, et al.Late cornified envelope family in differentiating epithelia—response to calcium and ultraviolet irradiation. J Invest Dermatol. 2005;124(5):1062–1070. doi:10.1111/j.0022-202X.2005.23699.x
24.
PajicPLinY-LXuDGokcumenO. The psoriasis-associated deletion of late cornified envelope genes LCE3B and LCE3C has been maintained under balancing selection since human denisovan divergence. BMC Evol Biol. 2016;16(1):265. doi:10.1186/s12862-016-0842-6
25.
NiehuesHTsoiLCvan der KriekenDA, et al.Psoriasis-associated late cornified envelope (LCE) proteins have antibacterial activity. J Invest Dermatol. 2017;137(11):2380–2388. doi:10.1016/j.jid.2017.06.003
26.
SunLCaoYHeN, et al.Association between LCE gene polymorphisms and psoriasis vulgaris among Mongolians from Inner Mongolia. Arch Dermatol Res. 2018;310(4):321–327. doi:10.1007/s00403-018-1813-0
27.
NiehuesHvan Vlijmen-WillemsIMJJBergboerJGM, et al.Late cornified envelope (LCE) proteins: distinct expression patterns of LCE2 and LCE3 members suggest nonredundant roles in human epidermis and other epithelia. Br J Dermatol. 2016;174(4):795–802. doi:10.1111/bjd.14284
28.
CaoXXYangJKWangL. Association between intercellular adhesion molecule 1 (ICAM1) polymorphisms and diabetic foot susceptibility: a case-control study. Medicine (Baltimore). 2020;99(11):e18052. doi:10.1097/MD.0000000000018052
29.
EliasANGoodmanMMRohanMK. Serum ICAM-1 concentrations in patients with psoriasis treated with antithyroid thioureylenes. Clin Exp Dermatol. 1993;18(6):526–529. doi:10.1111/j.1365-2230.1993.tb01022.x
30.
DowlatshahiEAVan Der VoortEAMArendsLRNijstenT.Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169(2):266–282. doi:10.1111/bjd.12355
31.
BressanALPiccianiBLSAzulay-AbulafiaL, et al.Evaluation of ICAM-1 expression and vascular changes in the skin of patients with plaque, pustular, and erythrodermic psoriasis. Int J Dermatol. 2018;57(2):209–216. doi:10.1111/ijd.13883
32.
DonnellPG.HughesJRHigginsEMGrovesRWPembrokeAC. A fatal case of capillary leak syndrome in erythrodermic psoriasis. Br J Dermatol. 1995;132(1):160–161. doi:10.1111/j.1365-2133.1995.tb08651.x
33.
SadehJSRudikoffDGordonMLBowdenJGoldmanBDLebwohlM. Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Dermatol. 1997;133(6):747–750. doi:10.1001/archderm.1997.03890420085010
34.
Guttman-YasskyEVugmeysterYLowesMA, et al.Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol. 2008;128(5):1182–1191. doi:10.1038/jid.2008.4
35.
SchwabNUlzheimerJCFoxRJ, et al.Fatal PML associated with efalizumab therapy insights into integrin αLβ2 in JC virus control. Neurology. 2012;78(7):458–467. doi:10.1212/WNL.0b013e3182478d4b
36.
FanXWangHSunL, et al.Fine mapping and subphenotyping implicates ADRA1B gene variants in psoriasis susceptibility in a Chinese population. Epigenomics. 2019;11(4):455–467. doi:10.2217/epi-2018-0131
37.
ZhongLKGanXXDengXY, et al.Potential five-mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma. Oncol Lett. 2020;20(3):2302–2310. doi:10.3892/ol.2020.11781
38.
WangTQinYLaiH, et al.The prognostic value of ADRA1 subfamily genes in gastric carcinoma. Oncol Lett. 2019;18(3):3150–3158. doi:10.3892/ol.2019.10660
39.
RoszkiewiczJMichałekDRykASwachaZSzmydBSmolewskaE.The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: results of a preliminary study. Int J Rheum Dis. 2020;23(11):1505–1513. doi:10.1111/1756-185X.13972
40.
YaoJK. Biosynthesis of membrane cholesterol during peripheral nerve development, degeneration and regeneration. Lipids. 1988;23(9):857–862. doi:10.1007/BF02536205
41.
ZhaoQSunYFuX, et al.Identification of a single nucleotide polymorphism in NFKBIA with different effects on psoriatic arthritis and cutaneous psoriasis in China. Acta Derm Venereol. 2018;99(1):84–88. doi:10.2340/00015555-3027
42.
Prieto-PérezRLlamas-VelascoMCabaleiroT, et al.Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017;18(2):157–164. doi:10.2217/pgs-2016-0122
43.
CaldarolaGSgambatoAFanaliC, et al.HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients. Pharmacogenet Genomics. 2016;26(9):423–427. doi:10.1097/FPC.0000000000000233
44.
ShacharSZivOAvkinS, et al.Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. EMBO J. 2009;28(4):383–393. doi:10.1038/emboj.2008.281
45.
GanGNWittschiebenJPWittschiebenBWoodRD. DNA polymerase zeta (pol) in higher eukaryotes. Cell Res. 2008;18(1):174–183. doi:10.1038/cr.2007.117
46.
SchentenDKrackerSEspositoG, et al.Pol zeta ablation in B cells impairs the germinal center reaction, class switch recombination, DNA break repair, and genome stability. J Exp Med. 2009;206(2):477–490. doi:10.1084/jem.20080669
47.
LangeSSBhetawalSRehSLeslie PowellKKusewittDFWoodRD. DNA polymerase ζ deficiency causes impaired wound healing and stress-induced skin pigmentation. Life Sci Alliance. 2018;1(3):e201800048. doi:10.26508/lsa.201800048
48.
GovindNChoudhuryAHodkinsonB, et al.Immunochip identifies novel, and replicates known, genetic risk loci for rheumatoid arthritis in black South Africans. Mol Med. 2014;20(1):341–349. doi:10.2119/molmed.2014.00097
49.
DolesJOliverTGCameronER, et al.Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A. 2010;107(48):20786–20791. doi:10.1073/pnas.1011409107
50.
ChengHLiYZuoXB, et al.Identification of a missense variant in LNPEP that confers psoriasis risk. J Invest Dermatol. 2014;134(2):359–365. doi:10.1038/jid.2013.317
51.
EstebanVRuperezMSánchez-LópezE, et al.Angiotensin IV activates the nuclear transcription factor-κB and related proinflammatory genes in vascular smooth muscle cells. Circ Res. 2005;96(9):965–973. doi:10.1161/01.RES.0000166326.91395.74
52.
NogueiraMPuigLTorresT. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–352. doi:10.1007/s40265-020-01261-8
53.
PappKGordonKThaçiD, et al.Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–1321. doi:10.1056/nejmoa1806382
54.
BanfieldCScaramozzaMZhangW, et al.The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clin Pharmacol. 2018;58(4):434–447. doi:10.1002/jcph.1046
55.
FormanSBPariserDMPoulinY, et al.TYK2/JAK1 Inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial. J Invest Dermatol. 2020;140(12):2359–2370.e5. doi:10.1016/j.jid.2020.03.962
56.
FotiadouCLazaridouESotiriouEIoannidesD. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl). 2018;8:1–5. doi:10.2147/ptt.s98893
57.
SavageLJWittmannMMcGonagleDHelliwellPS. Ustekinumab in the treatment of psoriasis and psoriatic arthritis. Rheumatol Ther. 2015;2(1):1–16. doi:10.1007/s40744-015-0010-2
58.
YaoYRichmanLMorehouseC, et al.Type I interferon: potential therapeutic target for psoriasis?PLoS One. 2008;3(7):e2737. doi:10.1371/journal.pone.0002737
59.
ConradCDi DomizioJMylonasA, et al.TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25. doi:10.1038/s41467-017-02466-4
60.
ZhangLJ. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis. Front Immunol. 2019;10:1440. doi:10.3389/fimmu.2019.01440
61.
ChangYTHsuCYChouCT, et al.The genetic polymorphisms of POU5F1 gene are associated with psoriasis vulgaris in Chinese. J Dermatol Sci. 2007;46(2):153–156. doi:10.1016/j.jdermsci.2007.01.003
62.
LeeKYLeungKSTangNLSWongMH. Discovering genetic factors for psoriasis through exhaustively searching for significant second order SNP-SNP interactions. Sci Rep. 2018;8(1):15186. doi:10.1038/s41598-018-33493-w
63.
GuoXEngelJLXiaoJ, et al.UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity. Proc Natl Acad Sci U S A. 2011;108(46):18649–18654. doi:10.1073/pnas.1113170108
64.
RouillardADGundersenGWFernandezNF, et al.The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford). 2016;2016:baw100. doi:10.1093/database/baw100
65.
GerberBOZanniMPUguccioniM, et al.Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol. 1997;7(11):836–843. doi:10.1016/S0960-9822(06)00371-X
66.
EliaG. MIG in psoriatic arthritis. Clin Ter. 2018;169(6):e297–e302. doi:10.7417/CT.2018.2097
67.
SzodorayPAlexPChappell-WoodwardCM, et al.Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford). 2007;46(3):417–425. doi:10.1093/rheumatology/kel306
68.
FiorinoASBaumSCzernikA, et al.570 Safety and efficacy of bertilimumab, a human anti-eotaxin-1 monoclonal antibody, in bullous pemphigoid in a phase 2a study. J Invest Dermatol. 2019;139(5):S98. doi:10.1016/j.jid.2019.03.646
69.
QianHWangMWangY, et al.Role of Galphaq in pathogenesis of psoriasis, a new mechanism about the immune regulation in psoriasis. Int Immunopharmacol. 2019;68:185–192. doi:10.1016/j.intimp.2018.12.054
70.
DolcinoMOttriaABarbieriA, et al.Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):e0128262. doi:10.1371/journal.pone.0128262
71.
SchwingenJKaplanMKurschusFC. Review—current concepts in inflammatory skin diseases evolved by transcriptome analysis: in-depth analysis of atopic dermatitis and psoriasis. Int J Mol Sci. 2020;21(3):699. doi:10.3390/ijms21030699
72.
BatliwallaFMLiWRitchlinCT, et al.Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med. 2005;11(1-12):21–29. doi:10.2119/2006-00003.Gulko
73.
NeumannEKhawajaKMüller-LadnerU. G protein-coupled receptors in rheumatology. Nat Rev Rheumatol. 2014;10(7):429–436. doi:10.1038/nrrheum.2014.62
74.
D’ambrosioDFreedmanMSPrinzJ. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016;7(1):18–33. doi:10.1177/2040622315617354
75.
MiyoshiKTakaishiMNakajimaK, et al.Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol. 2011;131(1):108–117. doi:10.1038/jid.2010.255
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
